[go: up one dir, main page]

WO1999009025A3 - Derives de 2-(4-aryl- ou heteroaryl-piperazin-1-ylmethyl)-1h-indole - Google Patents

Derives de 2-(4-aryl- ou heteroaryl-piperazin-1-ylmethyl)-1h-indole Download PDF

Info

Publication number
WO1999009025A3
WO1999009025A3 PCT/IB1998/001198 IB9801198W WO9909025A3 WO 1999009025 A3 WO1999009025 A3 WO 1999009025A3 IB 9801198 W IB9801198 W IB 9801198W WO 9909025 A3 WO9909025 A3 WO 9909025A3
Authority
WO
WIPO (PCT)
Prior art keywords
piperazin
ylmethyl
heteroaryl
receptor
aryl
Prior art date
Application number
PCT/IB1998/001198
Other languages
English (en)
Other versions
WO1999009025A2 (fr
Inventor
Anton Franz Josef Fliri
Mark Jerome Majchrzak
Patricia Ann Seymour
Stevin Howard Zorn
Hans Rollema
Original Assignee
Pfizer Prod Inc
Anton Franz Josef Fliri
Mark Jerome Majchrzak
Patricia Ann Seymour
Stevin Howard Zorn
Hans Rollema
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IL13396098A priority Critical patent/IL133960A0/xx
Priority to EP98935229A priority patent/EP1003739A2/fr
Priority to HU0003425A priority patent/HUP0003425A3/hu
Priority to AU84572/98A priority patent/AU8457298A/en
Priority to APAP/P/1998/001321A priority patent/AP9801321A0/en
Priority to CA002297486A priority patent/CA2297486C/fr
Priority to KR1020007001093A priority patent/KR20010022507A/ko
Priority to SK135-2000A priority patent/SK1352000A3/sk
Priority to PL98338947A priority patent/PL338947A1/xx
Application filed by Pfizer Prod Inc, Anton Franz Josef Fliri, Mark Jerome Majchrzak, Patricia Ann Seymour, Stevin Howard Zorn, Hans Rollema filed Critical Pfizer Prod Inc
Priority to BR9811557-0A priority patent/BR9811557A/pt
Priority to EA200000023A priority patent/EA200000023A1/ru
Priority to JP2000509706A priority patent/JP2002536291A/ja
Publication of WO1999009025A2 publication Critical patent/WO1999009025A2/fr
Publication of WO1999009025A3 publication Critical patent/WO1999009025A3/fr
Priority to BG104069A priority patent/BG104069A/xx
Priority to IS5336A priority patent/IS5336A/is
Priority to NO20000722A priority patent/NO20000722D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne un composé correspondant à la formule (I) dans laquelle a, T, V, X, Y, Z, R?1, R2, R3, R4, R5, R6, R7, R8 et R9¿ possèdent les notations données dans la description. Elle concerne également des sels de ce composé, acceptables sur le plan pharmacologique, ainsi que des compositions pharmaceutiques contenant de tels composés ou sels.
PCT/IB1998/001198 1997-08-15 1998-08-05 Derives de 2-(4-aryl- ou heteroaryl-piperazin-1-ylmethyl)-1h-indole WO1999009025A2 (fr)

Priority Applications (15)

Application Number Priority Date Filing Date Title
PL98338947A PL338947A1 (en) 1997-08-15 1998-08-05 Derivatives of 2-(4-aryl or heteroaryl piperazin-1-ylmethyl)-1h-indole
HU0003425A HUP0003425A3 (en) 1997-08-15 1998-08-05 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives and pharmaceutical compositions containing the compounds
AU84572/98A AU8457298A (en) 1997-08-15 1998-08-05 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives interacting with the dopamine D4 receptor
APAP/P/1998/001321A AP9801321A0 (en) 1997-08-15 1998-08-05 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-h-indole derivatives.
CA002297486A CA2297486C (fr) 1997-08-15 1998-08-05 Derives de 2-(4-aryl- ou heteroaryl-piperazin-1-ylmethyl)-1h-indole
KR1020007001093A KR20010022507A (ko) 1997-08-15 1998-08-05 도파민 디4 수용체와 상호작용하는 2-(4-아릴 또는헤테로아릴-피페라진-1-일메틸)-1수소-인돌 유도체
SK135-2000A SK1352000A3 (en) 1997-08-15 1998-08-05 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives interacting with the dopamine d4 receptor
IL13396098A IL133960A0 (en) 1997-08-15 1998-08-05 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives
BR9811557-0A BR9811557A (pt) 1997-08-15 1998-08-05 Derivados do 2-)4-aril ou heteroaril-piperazin-1-ilmetil)-1h-indol
EP98935229A EP1003739A2 (fr) 1997-08-15 1998-08-05 Derives de 2-(4-aryl- ou heteroaryl-piperazin-1-ylmethyl)-1h-indole
EA200000023A EA200000023A1 (ru) 1997-08-15 1998-08-05 Производные 2-(-4-арил или гетероарил-пиперазин-1-илметил) -1h-индола
JP2000509706A JP2002536291A (ja) 1997-08-15 1998-08-05 ２−（４−アリール又はヘテロアリール−ピペラジン−１−イルメチル）−１ｈ−インドール誘導体
BG104069A BG104069A (en) 1997-08-15 2000-01-10 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives interacting with the dopamine d4 receptor
IS5336A IS5336A (is) 1997-08-15 2000-01-11 2-(4-Arýl eða heteróarýl-píperazín-1-ýlmetýl)-1H-indól afleiður
NO20000722A NO20000722D0 (no) 1997-08-15 2000-02-14 2-(4-aryl eller heteroaryl-piperazin-1-ylmetyl)-1H- indolderivater

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5576497P 1997-08-15 1997-08-15
US60/055,764 1997-08-15

Publications (2)

Publication Number Publication Date
WO1999009025A2 WO1999009025A2 (fr) 1999-02-25
WO1999009025A3 true WO1999009025A3 (fr) 1999-04-15

Family

ID=22000003

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1998/001198 WO1999009025A2 (fr) 1997-08-15 1998-08-05 Derives de 2-(4-aryl- ou heteroaryl-piperazin-1-ylmethyl)-1h-indole

Country Status (30)

Country Link
EP (1) EP1003739A2 (fr)
JP (1) JP2002536291A (fr)
KR (1) KR20010022507A (fr)
CN (1) CN1265660A (fr)
AP (1) AP9801321A0 (fr)
AR (1) AR017019A1 (fr)
AU (1) AU8457298A (fr)
BG (1) BG104069A (fr)
BR (1) BR9811557A (fr)
CA (1) CA2297486C (fr)
CO (1) CO4960656A1 (fr)
DZ (1) DZ2583A1 (fr)
EA (1) EA200000023A1 (fr)
HR (1) HRP980441A2 (fr)
HU (1) HUP0003425A3 (fr)
ID (1) ID23803A (fr)
IL (1) IL133960A0 (fr)
IS (1) IS5336A (fr)
MA (1) MA24632A1 (fr)
NO (1) NO20000722D0 (fr)
OA (1) OA11286A (fr)
PA (1) PA8457001A1 (fr)
PE (1) PE106299A1 (fr)
PL (1) PL338947A1 (fr)
SK (1) SK1352000A3 (fr)
TN (1) TNSN98151A1 (fr)
TR (1) TR200000414T2 (fr)
UY (1) UY25144A1 (fr)
WO (1) WO1999009025A2 (fr)
ZA (1) ZA987304B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1027336T3 (da) * 1997-10-27 2005-01-24 Neurosearch As Heteroaryldiazacycloalkaner, deres fremstilling og anvendelse
EP0953567A3 (fr) * 1998-04-29 2003-04-02 Pfizer Products Inc. Dérivés de piperazin-, piperidine- et tetrahydropyridine bicyclique substitués, leur préparation et leur utilisation comme agents a activité dopaminergique (recepteur D4 de la dopamine) centrale
DK1464641T3 (da) * 1999-12-30 2008-08-18 Lundbeck & Co As H 4-phenylpiperazinyl-, -piperidinyl- og -tetrahydropyridylderivater som dopamin-D4-antagonister
GB0017952D0 (en) * 2000-07-22 2000-09-13 Univ Manchester Treatment of dyskinesia
EP1177792A3 (fr) 2000-07-27 2002-10-23 Pfizer Products Inc. Ligands dopamine d4 destines au traitement des troubles associees a la cherche de la nouveaute
WO2002072548A2 (fr) * 2001-03-09 2002-09-19 Ortho-Mcneil Pharmaceutical, Inc. Composes heterocycliques
NZ538401A (en) 2002-09-06 2008-03-28 Janssen Pharmaceutica Nv (1H-benzoimidazol-2-yl)-(piperazinyl)-methanone derivatives and related compounds as histamine H4-receptor antagonists for the treatment of inflammatory and allergic disorders
WO2004108671A1 (fr) * 2003-06-06 2004-12-16 Suven Life Sciences Limited Indoles substitues dotes d'une affinite pour le recepteur de la serotonine, leur procede de fabrication et compositions pharmaceutiques les contenant
WO2005095338A1 (fr) 2004-03-30 2005-10-13 Takeda Pharmaceutical Company Limited Dérivés de l’acide alkoxyphénylpropanoïque
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
US7618980B2 (en) 2004-07-14 2009-11-17 Bristol-Myers Squibb Company Pyrrolo(oxo)quinolines as 5HT ligands
JO2769B1 (en) * 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
JO2642B1 (en) * 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
JO2849B1 (en) * 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
DK2148873T3 (da) 2007-04-23 2012-11-26 Janssen Pharmaceutica Nv 4-alkoxypyridazinderivater som hurtigt dissocierende dopamin 2- receptorantagonister
MX2009011416A (es) 2007-04-23 2009-11-05 Janssen Pharmaceutica Nv Tia(di)azoles como antagonistas del receptor de dopamina 2 de disociacion rapida.
AU2009266001B2 (en) 2008-07-03 2014-03-27 Janssen Pharmaceutica Nv Substituted 6- (1-piperazinyl) -pyridazines as 5-HT6 receptor antagonists
SI2307374T1 (sl) 2008-07-31 2017-05-31 Janssen Pharmaceutica Nv Piperazin-1-il-trifluorometil-substituirani-piridini kot hitro disociirajoči antagonisti receptorja dopamin 2
JP7548814B2 (ja) * 2017-09-20 2024-09-10 ハンジョウ イノゲート ファーマ カンパニー リミテッド Ｉｄｏ阻害剤および／またはｉｄｏ－ｈｄａｃ二重阻害剤としての多環式化合物
AU2021259580A1 (en) * 2020-04-22 2022-11-24 Anima Biotech Inc. Collagen 1 translation inhibitors and methods of use thereof

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3188313A (en) * 1959-09-25 1965-06-08 Sterling Drug Inc 1-[(1-, 2- and 3-indolyl)-lower]piperazine derivatives and intermediates and processes for the preparation thereof
WO1993001181A1 (fr) * 1991-07-03 1993-01-21 The Upjohn Company Indoles substitues utilises comme produits pharmaceutiques dans le traitement du sida
EP0548798A1 (fr) * 1991-12-18 1993-06-30 Sanwa Kagaku Kenkyusho Co., Ltd. Agent antiviral
WO1994010162A1 (fr) * 1992-10-23 1994-05-11 Merck Sharp & Dohme Limited Ligands pour les sous-types de recepteurs de dopamine
WO1994021628A1 (fr) * 1993-03-18 1994-09-29 Merck Sharp & Dohme Limited Derives de l'indole en tant qu'antagonistes de la dopamine d4
WO1994021627A1 (fr) * 1993-03-18 1994-09-29 Merck Sharp & Dohme Limited Derives indoliques servant d'antagonistes de dopamine d4
WO1994024105A1 (fr) * 1993-04-15 1994-10-27 Merck Sharp & Dohme Limited Derives d'indole utiles comme antagonistes de la dopamine d4
EP0683166A1 (fr) * 1994-04-22 1995-11-22 MERCK PATENT GmbH 3-Indolylpipéridines
WO1996018628A1 (fr) * 1994-12-13 1996-06-20 Pharmacia & Upjohn Company Composes de piperadinyle et piperazinyle anti-sida a substitution alkyle
WO1997019089A1 (fr) * 1995-11-17 1997-05-29 Pharmacia & Upjohn Company Agent anti-bacterien a base d'oxazolidinone a substituants tricycliques
WO1997043279A1 (fr) * 1996-05-10 1997-11-20 Janssen Pharmaceutica N.V. Derives de la 2,4-diaminopyrimidine utilises comme antagonistes du recepteur d4 de la dopamine

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3188313A (en) * 1959-09-25 1965-06-08 Sterling Drug Inc 1-[(1-, 2- and 3-indolyl)-lower]piperazine derivatives and intermediates and processes for the preparation thereof
WO1993001181A1 (fr) * 1991-07-03 1993-01-21 The Upjohn Company Indoles substitues utilises comme produits pharmaceutiques dans le traitement du sida
EP0548798A1 (fr) * 1991-12-18 1993-06-30 Sanwa Kagaku Kenkyusho Co., Ltd. Agent antiviral
WO1994010162A1 (fr) * 1992-10-23 1994-05-11 Merck Sharp & Dohme Limited Ligands pour les sous-types de recepteurs de dopamine
WO1994021628A1 (fr) * 1993-03-18 1994-09-29 Merck Sharp & Dohme Limited Derives de l'indole en tant qu'antagonistes de la dopamine d4
WO1994021627A1 (fr) * 1993-03-18 1994-09-29 Merck Sharp & Dohme Limited Derives indoliques servant d'antagonistes de dopamine d4
WO1994024105A1 (fr) * 1993-04-15 1994-10-27 Merck Sharp & Dohme Limited Derives d'indole utiles comme antagonistes de la dopamine d4
EP0683166A1 (fr) * 1994-04-22 1995-11-22 MERCK PATENT GmbH 3-Indolylpipéridines
WO1996018628A1 (fr) * 1994-12-13 1996-06-20 Pharmacia & Upjohn Company Composes de piperadinyle et piperazinyle anti-sida a substitution alkyle
WO1997019089A1 (fr) * 1995-11-17 1997-05-29 Pharmacia & Upjohn Company Agent anti-bacterien a base d'oxazolidinone a substituants tricycliques
WO1997043279A1 (fr) * 1996-05-10 1997-11-20 Janssen Pharmaceutica N.V. Derives de la 2,4-diaminopyrimidine utilises comme antagonistes du recepteur d4 de la dopamine

Also Published As

Publication number Publication date
JP2002536291A (ja) 2002-10-29
HUP0003425A3 (en) 2002-02-28
AR017019A1 (es) 2001-08-22
PA8457001A1 (es) 2000-09-29
CA2297486A1 (fr) 1999-02-25
BG104069A (en) 2001-05-31
CN1265660A (zh) 2000-09-06
OA11286A (en) 2003-10-22
DZ2583A1 (fr) 2003-02-22
NO20000722L (no) 2000-02-14
PL338947A1 (en) 2000-12-04
MA24632A1 (fr) 1999-04-01
AU8457298A (en) 1999-03-08
WO1999009025A2 (fr) 1999-02-25
NO20000722D0 (no) 2000-02-14
PE106299A1 (es) 1999-11-02
KR20010022507A (ko) 2001-03-15
ZA987304B (en) 2000-02-14
UY25144A1 (es) 2000-12-29
TNSN98151A1 (fr) 2005-03-15
IL133960A0 (en) 2001-04-30
IS5336A (is) 2000-01-11
EP1003739A2 (fr) 2000-05-31
HRP980441A2 (en) 1999-04-30
SK1352000A3 (en) 2000-08-14
ID23803A (id) 2000-05-11
CA2297486C (fr) 2005-05-03
CO4960656A1 (es) 2000-09-25
TR200000414T2 (tr) 2000-08-21
HUP0003425A2 (hu) 2001-10-28
BR9811557A (pt) 2000-08-22
EA200000023A1 (ru) 2000-08-28
AP9801321A0 (en) 2000-02-14

Similar Documents

Publication Publication Date Title
WO1999009025A3 (fr) Derives de 2-(4-aryl- ou heteroaryl-piperazin-1-ylmethyl)-1h-indole
CA2105114A1 (fr) Chlorhydrate monohydrate de 5-(2-(4-(1,2 benzisothiazol-3-yl)-1- piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
IL124537A0 (en) Naphthyl-substituted benzimidazole derivatives and pharmaceutical compositions containing the same
GEP20053474B (en) Glucocorticoid Receptor Modulators
AU1200695A (en) 4,5-diaryloxazole derivatives
CA2274669A1 (fr) Derives de 1,5-benzodiazepine
CA2317462A1 (fr) Composes de 4-(2-ceto-1-benzimidazolinyl)piperidine, utiles comme agonistes du recepteur orl1
CA2288122A1 (fr) Antagoniste de recepteur de neuropeptide y
AU2337097A (en) Meta-substituted phenylene derivatives and their use as alphavbeta3 integrin antagonists or inhibitors
AU2420897A (en) Meta-substituted phenylene sulphonamide derivatives
CA2166800A1 (fr) Derives de piperidine 4-substitues comme antagonistes de la neurokinine
AU1247195A (en) Cyclic amide derivatives as neurokinin a antagonists
NZ240378A (en) Substituted thiazolidinedione derivatives; pharmaceutical compositions,
NO996108L (no) 9-oksinerytromycinderivater
CA2373117A1 (fr) Derives de 13-methyl-erythromycine
EP0924207A4 (fr) Derives de chromene-3-carboxylate
CA2120028A1 (fr) Derives indole pour le traitement de la migraine
WO1999012570A3 (fr) Procede, compositions et trousses servant a augmenter la biodisponibilite orale d'agents pharmaceutiques
CA2138289A1 (fr) Derives azabicycloheptane substitues en n, leur preparation et leur utilisation
EP1057813A4 (fr) Derives de l'indole et compositions medicales les renfermant
BG104447A (en) Biphenylamidine derivatives
NZ240575A (en) N-benzoylproline derivatives and pharmaceutical compositions
HU9801950D0 (en) 2-(arylphenyl)-amino-imidazoline derivatives
WO2001010860A3 (fr) Derives de quinazolinone et d'azaquinazolinone
CA2112083A1 (fr) Composes aryliques heterocycliques substitues

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 133960

Country of ref document: IL

Ref document number: P-26/00

Country of ref document: YU

Ref document number: 98807831.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 84572/98

Country of ref document: AU

Ref document number: 502282

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2297486

Country of ref document: CA

Ref document number: 2297486

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200000023

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: PV2000-307

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1352000

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 1020007001093

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1998935229

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/001611

Country of ref document: MX

Ref document number: 2000/00414

Country of ref document: TR

WWP Wipo information: published in national office

Ref document number: 1998935229

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09423064

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: PV2000-307

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020007001093

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: 1020007001093

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1998935229

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV2000-307

Country of ref document: CZ